Browse PPP3CA

Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Cell membrane, sarcolemma Nucleus Note=Colocalizes with ACTN1 and MYOZ2 at the Z line in heart and skeletal muscle.
Domain PF00149 Calcineurin-like phosphoesterase
Function

Calcium-dependent, calmodulin-stimulated protein phosphatase. Many of the substrates contain a PxIxIT motif. This subunit may have a role in the calmodulin activation of calcineurin. Dephosphorylates DNM1L, HSPB1 and SSH1.

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0001678 cellular glucose homeostasis
GO:0001975 response to amphetamine
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002792 negative regulation of peptide secretion
GO:0003012 muscle system process
GO:0003299 muscle hypertrophy in response to stress
GO:0003300 cardiac muscle hypertrophy
GO:0006470 protein dephosphorylation
GO:0006606 protein import into nucleus
GO:0006816 calcium ion transport
GO:0006913 nucleocytoplasmic transport
GO:0007159 leukocyte cell-cell adhesion
GO:0007223 Wnt signaling pathway, calcium modulating pathway
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0009306 protein secretion
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009914 hormone transport
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010611 regulation of cardiac muscle hypertrophy
GO:0010612 regulation of cardiac muscle adaptation
GO:0010613 positive regulation of cardiac muscle hypertrophy
GO:0010615 positive regulation of cardiac muscle adaptation
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010771 negative regulation of cell morphogenesis involved in differentiation
GO:0010817 regulation of hormone levels
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0014075 response to amine
GO:0014706 striated muscle tissue development
GO:0014733 regulation of skeletal muscle adaptation
GO:0014742 positive regulation of muscle hypertrophy
GO:0014743 regulation of muscle hypertrophy
GO:0014744 positive regulation of muscle adaptation
GO:0014883 transition between fast and slow fiber
GO:0014887 cardiac muscle adaptation
GO:0014888 striated muscle adaptation
GO:0014896 muscle hypertrophy
GO:0014897 striated muscle hypertrophy
GO:0014898 cardiac muscle hypertrophy in response to stress
GO:0014902 myotube differentiation
GO:0014904 myotube cell development
GO:0015833 peptide transport
GO:0016055 Wnt signaling pathway
GO:0016311 dephosphorylation
GO:0016358 dendrite development
GO:0017038 protein import
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0022604 regulation of cell morphogenesis
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0031345 negative regulation of cell projection organization
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0033173 calcineurin-NFAT signaling cascade
GO:0033500 carbohydrate homeostasis
GO:0033555 multicellular organismal response to stress
GO:0034284 response to monosaccharide
GO:0034504 protein localization to nucleus
GO:0035561 regulation of chromatin binding
GO:0035562 negative regulation of chromatin binding
GO:0035567 non-canonical Wnt signaling pathway
GO:0035690 cellular response to drug
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042110 T cell activation
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042391 regulation of membrane potential
GO:0042493 response to drug
GO:0042593 glucose homeostasis
GO:0042692 muscle cell differentiation
GO:0042886 amide transport
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0042993 positive regulation of transcription factor import into nucleus
GO:0043500 muscle adaptation
GO:0043501 skeletal muscle adaptation
GO:0043502 regulation of muscle adaptation
GO:0044057 regulation of system process
GO:0044744 protein targeting to nucleus
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045665 negative regulation of neuron differentiation
GO:0046676 negative regulation of insulin secretion
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046888 negative regulation of hormone secretion
GO:0048016 inositol phosphate-mediated signaling
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048741 skeletal muscle fiber development
GO:0048747 muscle fiber development
GO:0048813 dendrite morphogenesis
GO:0048814 regulation of dendrite morphogenesis
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050768 negative regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0050774 negative regulation of dendrite morphogenesis
GO:0050796 regulation of insulin secretion
GO:0050804 modulation of synaptic transmission
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051146 striated muscle cell differentiation
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051224 negative regulation of protein transport
GO:0051531 NFAT protein import into nucleus
GO:0051532 regulation of NFAT protein import into nucleus
GO:0051533 positive regulation of NFAT protein import into nucleus
GO:0051592 response to calcium ion
GO:0051961 negative regulation of nervous system development
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0060078 regulation of postsynaptic membrane potential
GO:0060079 excitatory postsynaptic potential
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070838 divalent metal ion transport
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0071593 lymphocyte aggregation
GO:0072511 divalent inorganic cation transport
GO:0090087 regulation of peptide transport
GO:0090257 regulation of muscle system process
GO:0090276 regulation of peptide hormone secretion
GO:0090278 negative regulation of peptide hormone secretion
GO:0090316 positive regulation of intracellular protein transport
GO:0097720 calcineurin-mediated signaling
GO:0099565 chemical synaptic transmission, postsynaptic
GO:0198738 cell-cell signaling by wnt
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1902593 single-organism nuclear import
GO:1903242 regulation of cardiac muscle hypertrophy in response to stress
GO:1903244 positive regulation of cardiac muscle hypertrophy in response to stress
GO:1903531 negative regulation of secretion by cell
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904950 negative regulation of establishment of protein localization
GO:1904951 positive regulation of establishment of protein localization
GO:2000171 negative regulation of dendrite development
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0004722 protein serine/threonine phosphatase activity
GO:0004723 calcium-dependent protein serine/threonine phosphatase activity
GO:0005516 calmodulin binding
GO:0008144 drug binding
GO:0016791 phosphatase activity
GO:0033192 calmodulin-dependent protein phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
GO:0046982 protein heterodimerization activity
Cellular Component GO:0005955 calcineurin complex
GO:0008287 protein serine/threonine phosphatase complex
GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030018 Z disc
GO:0031674 I band
GO:0042383 sarcolemma
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
GO:0098794 postsynapse
GO:1903293 phosphatase complex
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04020 Calcium signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04114 Oocyte meiosis
hsa04310 Wnt signaling pathway
hsa04360 Axon guidance
hsa04370 VEGF signaling pathway
hsa04380 Osteoclast differentiation
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04720 Long-term potentiation
hsa04724 Glutamatergic synapse
hsa04728 Dopaminergic synapse
hsa04921 Oxytocin signaling pathway
hsa04922 Glucagon signaling pathway
Reactome R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5607763: CLEC7A (Dectin-1) induces NFAT activation
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-4086398: Ca2+ pathway
R-HSA-180024: DARPP-32 events
R-HSA-2871809: FCERI mediated Ca+2 mobilization
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-111885: Opioid Signalling
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-195721: Signaling by Wnt
Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPP3CA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PPP3CA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25185261lymphomaPromote immunityOur results demonstrate that CNA12-CTL induce regression of EBV-associated tumors in vivo despite ongoing immunosuppression.
Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPP3CA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPP3CA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0020.996
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3460.855
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2570.844
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4260.0827
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2550.9
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6440.795
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0950.812
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0420.979
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1710.922
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3510.748
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.850.6
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0760.31
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPP3CA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPP3CA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPP3CA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPP3CA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPP3CA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPP3CA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPP3CA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPP3CA
Nameprotein phosphatase 3, catalytic subunit, alpha isozyme
Aliases PPP2B; calcineurin A alpha; protein phosphatase 2B, catalytic subunit, alpha isoform; CALN; CALNA; protein p ......
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPP3CA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PPP3CA.
ID Name Drug Type Targets #Targets
DB08231Myristic acidSmall MoleculeABL1, ARF1, ARF6, ECI2, FKBP1A, GM2A, GUCA1A, HNF4A, INS, LY96, NC ......20